Provided by Tiger Trade Technology Pte. Ltd.

CG Oncology Inc.

79.81
+2.202.83%
Volume:701.78K
Turnover:55.67M
Market Cap:7.07B
PE:-29.30
High:79.89
Open:78.69
Low:77.38
Close:77.61
52wk High:80.97
52wk Low:25.25
Shares:88.64M
Float Shares:64.73M
Volume Ratio:0.97
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7235
EPS(LYR):-2.0826
ROE:-26.41%
ROA:-17.67%
PB:6.87
PE(LYR):-38.32

Loading ...

Company Profile

Company Name:
CG Oncology Inc.
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
- -
Office Location:
3000 Pegasus Park Drive,Suite 1640,Dallas,Texas,United States
Zip Code:
75247
Fax:
- -
Introduction:
CG Oncology, Inc. was originally incorporated in California on September 24, 2010, and later reincorporated in Delaware on November 30, 2017. The company is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for the treatment of bladder cancer. Its clinical programs target patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer who have limited treatment options.

Directors

Name
Position
Arthur Kuan
Chairman of the Board and Chief Executive Officer
Brian Liu
Independent Director
Hong Fang Song
Independent Director
James J. Mulé
Independent Director
Leonard Post
Lead Independent Director
Susan Graf
Independent Director
Victor Tong
Independent Director

Shareholders

Name
Position
Arthur Kuan
Chairman of the Board and Chief Executive Officer
Ambaw Bellete
President and Chief Operating Officer
Jim DeTore
Principal Financial and Accounting Officer
Joshua F. Patterson
General Counsel and Chief Compliance Officer
Vijay Kasturi
Chief Medical Officer